Neurophth Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series D

  • Investors
  • 18

Neurophth General Information

Description

Developer of gene therapy products designed for the treatment of genetic ophthalmic diseases. The company's technology utilizes a proprietary adeno-associated virus platform and mitochondria codon-optimized gene delivery, providing ophthalmic patients with gene therapy drugs, retinal disease treatments, glaucoma medications, vascular retinopathy therapies, and optic neuroprotection agents to address genetic eye disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3rd Floor, Building B3, Phase II, Innovation Park
  • Number 1 Jiufeng 1st Road, East Lake High-tech Development Zone
  • Wuhan, Hubei 430000
  • China
+86 027
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3rd Floor, Building B3, Phase II, Innovation Park
  • Number 1 Jiufeng 1st Road, East Lake High-tech Development Zone
  • Wuhan, Hubei 430000
  • China
+86 027

Neurophth Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurophth Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series D) 21-Aug-2026 Completed Generating Revenue
8. Later Stage VC (Series C1) 09-Aug-2023 Completed Generating Revenue
7. Later Stage VC 20-Apr-2023 Completed Generating Revenue
6. Secondary Transaction - Private 20-Apr-2023 Completed Generating Revenue
5. Secondary Transaction - Private 03-Nov-2022 Completed Clinical Trials - General
4. Later Stage VC (Series C) 04-Nov-2021 Completed Clinical Trials - General
3. Early Stage VC (Series B) 05-Feb-2021 Completed Clinical Trials - General
2. Early Stage VC (Series A) 17-Dec-2019 $18.5M $20.8M Completed Pre-Clinical Trials
1. Early Stage VC 01-Jul-2018 $2.32M $2.32M Completed Pre-Clinical Trials
To view Neurophth’s complete valuation and funding history, request access »

Neurophth Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene therapy products designed for the treatment of genetic ophthalmic diseases. The company's technology u
Drug Discovery
Wuhan, China

Shanghai, China
 

Ann Arbor, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurophth Competitors (3)

One of Neurophth’s 3 competitors is Arctic Vision, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arctic Vision Venture Capital-Backed Shanghai, China
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Pfizer (Vienna) Corporation Vienna, Austria
You’re viewing 3 of 3 competitors. Get the full list »

Neurophth Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guangzhou Financial Holdings Corporation Minority
Hubei Provincial Science and Technology Investment Group Venture Capital Minority
Hubei Yangtze River Industrial Investment Group Government Minority
Optics Valley Financial Holdings Group Corporation Minority
Wuhan High Tech Medical Instrument Park Corporation Minority
You’re viewing 5 of 18 investors. Get the full list »

Neurophth FAQs

  • When was Neurophth founded?

    Neurophth was founded in 2016.

  • Where is Neurophth headquartered?

    Neurophth is headquartered in Wuhan, China.

  • What industry is Neurophth in?

    Neurophth’s primary industry is Drug Discovery.

  • Is Neurophth a private or public company?

    Neurophth is a Private company.

  • What is Neurophth’s current revenue?

    The current revenue for Neurophth is .

  • How much funding has Neurophth raised over time?

    Neurophth has raised $146M.

  • Who are Neurophth’s investors?

    Guangzhou Financial Holdings, Hubei Provincial Science and Technology Investment Group, Hubei Yangtze River Industrial Investment Group, Optics Valley Financial Holdings Group, and Wuhan High Tech Medical Instrument Park are 5 of 18 investors who have invested in Neurophth.

  • Who are Neurophth’s competitors?

    Arctic Vision, ONL Therapeutics, and Pfizer (Vienna) are competitors of Neurophth.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process